ArticleCancer & metabolism2016
Pre-diagnosis blood glucose and prognosis in women with breast cancer.
Article in Cancer & metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.Breast cancer research and treatment · 2026Article
- The role of glycemic control and symptoms and symptom clusters in breast cancer survivors with type 2 diabetes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Obesity Associated with Prediabetes Increases the Risk of Breast Cancer Development and Progression-A Study on an Obese Rat Model with Impaired Glucose Tolerance.International journal of molecular sciences · 2023Article
- Metabolic abnormalities and survival among patients with non-metastatic breast cancer.BMC cancer · 2022Article
- Association of hypertension, hyperlipidemia, obesity, and demographic risk factors with breast cancer in Bangladeshi women.Medicine · 2022Article
- Intermittent fasting during adjuvant chemotherapy may promote differential stress resistance in breast cancer patients.Journal of the Egyptian National Cancer Institute · 2022Article
- Article
- Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.BMC cancer · 2021Article
- Predictive Factors Among Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in T1-T2 Breast Cancer.Cancer management and research · 2021Article
- Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study.Breast cancer research and treatment · 2020Observational
- Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality.Cancers · 2019Review
- p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.Cell reports · 2019Article
- Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.Breast cancer research and treatment · 2019Article
- Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation.Cancer & metabolism · 2018Article
- Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation.Medical oncology (Northwood, London, England) · 2017Review
- De Ritis ratio in elderly glioblastoma patients treated with chemoradiation: A comprehensive analysis of serum biomarkers.Neuro-oncology advancesArticle
- Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization.Diabetes & metabolic syndromeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe effect of moderately elevated blood glucose levels among non-diabetic subjects on cancer prognosis is not well described. The goal of this study was to examine the association of elevated random blood glucose (RBG) levels in non-diabetic breast cancer patients with overall survival (OS) and time to tumor recurrence (TTR).
resultsForty-nine deaths and 32 recurrences occurred among 148 eligible study subjects during 855.44 person-years of follow-up, with median follow-up of 5.97 years. We observed that patients with elevated RBG levels experienced significantly shorter OS (hazard ratio [HR], 3.01; 95 % confidence interval [CI] (1.70-5.33); P < 0.001) and shorter TTR (HR, 2.08; CI (1.04-4.16); P = 0.04) as compared to patients with non-elevated RBG levels. After controlling for tumor grade, tumor stage, race, and BMI, elevated RBG continued to display high and statistically significant association with shorter OS (HR, 3.50; CI (1.87-6.54); P < 0.001). Adjustment for age, race, and BMI strengthened HR of RBG for TTR. The association of RGB with TTR lost its borderline statistical significance upon controlling for both tumor grade and stage.
conclusionsThe data suggest that elevated blood glucose is associated with poor prognosis of breast cancer patients. Given the potential clinical implication, these findings warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.